Overview

TAS-102 and Anlotinib in ≥3 Lines mGC

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang University